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Introduction
Heparin-induced thrombocytopenia(HIT) is an acquired thrombocytopeniam ediated by anti-heparin/platelet factor 4( PF4) antibodiesinthe setting of heparin therapy. Affected patients are at substantial riskf or arterial and venous thromboticc omplications (1) (2) (3) (4) .While HITisdefinedasthrombocytopenia in the presenceo fh eparin-induced antibodies( HIA), manyp atients exposed to heparin acquire HIAi nt he absence of thrombocytopenia. Up to 50% of cardiacsurgerypatients will develop HIA, although only2 %o ft hese patients will also have thrombocytopenia (5) . Somereportssuggest that HIAeveninthe absence of thrombocytopenia are an independent predictor of myocardial infarction in patients with acute coronaryi schemic syndromes (6) , although others have not confirmed this (7) .
Patients with chronic kidney disease (CKD) areathigh risk for cardiovascular events. Five-year survivalo fp atients on hemodialysis (HD) is less than50% (8) .More than half of this mortality is related to myocardialinfarction alone,but other arterial eventsi ncluding strokea nd peripheral arteryd iseasea re also highly prevalent. Ve nous thromboembolic eventsa lso occur in HD patients, butdataregarding incidenceare scarce (9, 10) . Additionally, vasculara ccesso cclusion occursi n3 3-56% of HD patients and leads to annualc osts exceeding $1 billion in the UnitedStates (11, 12) .
Known cardiovascularrisk factorsdonot entirely account for the high cardiovasculardisease-related morbidity and mortality in these patients (13) . Several reports, most of themb ased on small patient cohorts, have analysed the frequencyofHIA in patients chronically exposed to heparin in the setting of HD.However,t hese studies were notd esignedt oa ssess the clinical relevance of these antibodies. Hence,wesought to test the hypothesis that HIAare a"non-traditional" cardiovascularrisk factor in this population usingt ime to event analysis. Thea ims of this studyw ere (i)t od etermine the prevalenceo fH IA in patients treated by dialysis, (ii) to determine the prevalenceo ft hrombocytopenia and HITi nt his group of patients, and (iii) to test whether HIA are associatedwith adverseoutcomes including arterial cardiovasculare vents, venous thromboembolic events, eventsofvascular accessocclusion, and mortality.
Methods

Patientpopulation and blood sampling
The study subjects were asubpopulation of patients participating in the Choicesf or HealthyO utcomes in Caring for End-Stage RenalDisease(CHOICE)CohortStudy (14, 15) . CHOICE is a national,prospectivecohortstudy of incident HD and peritoneal dialysis (PD) patients initiatedin1995 to investigatetreatment choices of modality and dose and outcomeso fd ialysis care. From October 1995 to June 1998, 1,041 (767 HD and 274 PD) patients were enrolledf rom 81 dialysis clinicsa ssociatedw ith Dialysis Clinic, Incorporated (DCI, Nashville,TN, USA), New HavenCAPD(NewHaven, CT,USA), and the HospitalofSaint Raphael (NewHaven, CT,USA) (Fig. 1 ). All study participants were incident kidney failurepatients starting outpatient dialysis, were over 17 years of age, and spokeEnglishorSpanish. Patients were enrolledam edian of 45 days fromi nitiation of chronic dialysis (98% within 4months). The meanduration of follow-up was3.6 years (5 th and 95 th percentiles, 5.8 months and 9.1 years, respectively).F ollow-up wascomplete (100%)inregard to cardiovascular mortality.The prospectively designedstudy wasapprovedbythe Johns Hopkins University School of Medicine Institutional ReviewBoardprior to the initiation of HIAtesting.
Routineblood draw sera,collectedasclose as possible to six months after the first dialysis (mean time to testing 5.7 months, 5 th and 95 th percentile: 71 days and 1.1 years), were available from 740d ialysis (HDa nd PD) patients. HD patients were chronicallyexposed to heparin during dialysis, whereas PD patientsputatively were not. The301 patients that could not be includedinthe study due to lackofa vailableserum samples had similar baseline characteristics compared to patients thatw ere includedinthe study.The excluded patients did not differ by sex, hypertension, diabetes, smoking status, albumin, cholesterol, triglyceride levels and body mass index(BMI). They did tend to be younger,were less likelytobewhite, were less likelytohave an elevatedcomorbidityscore(ICED =3; see "baseline datacollection" for definition) and had higher creatinine, higher lowdensity lipoproteins (LDL) cholesterol and lowerC-reactive protein (CRP).
Outcomes
Our outcomes of interest were thrombocytopenia and four clinical outcomes. Plateletc ounts were obtainedf rom routine monthly blood drawd atap rovided by the clinics. Thrombocytopenia wasd efineda sap lateletc ount below1 50 G/l (150,000/µl) or adecreaseof50% or more from apreviousplateletc ount. Mortality wasa scertainedf rom dialysis centre reports, medicalrecords,and data from the CMS and the National Death Index(NDI). Arterial cardiovascular eventsincludedany of the following eventsduring the follow-up period: myocardial infarction, cerebrovasculara ccident, coronarya rteryb ypass graft,percutaneous coronaryangioplasty,peripheral artery bypass, amputation, abdominal aortic aneurysm repair,c arotid endarterectomy,and sudden coronarydeath. Theseevents were identifiedi nh ospitalisation records, revieweda nd adjudicated by twomembersofthe study'soutcomes committee using uniformlyapplied criteria modified from the CardiovascularHealth Study (16) , HEMOstudy (17), or,inthe absence of an adjudicated record, from CMS hospitalisationdata. Deep vein thrombosis and pulmonary embolism eventsw ere identifiedinCMS hospitalisation data as definedb yI CD-9-CMc odes (451.1x, 451.2, 451.81, 451.83, 451.89, 452.x, 453.x and 415.1x). Finally, vascularaccessinformation wasobtained through reviewofdischarge summaries, dialysis flowsheets, and dialysis clinic progress notes, as describedelsewhere (18) .All vascularaccessocclusion eventswere reviewed,and onlythose codedasthrombosis-related were used as outcomesinthis study.
Baseline datacollection
Demographic characteristics, primaryc auseo fk idneyf ailure, and dateo ff irst chronic dialysis were ascertainedf rom the Centres forMedicare &MedicaidServices (CMS) Medical EvidenceF orm(Form 2728), whichw as completed at initiation of chronic dialysis. Racewas categorised as black, white,orother (including Native American and Asian). Comorbidity assessmentwas performed at enrolment usingthe IndexofCoexistent Disease (ICED), acomposite scoring system basedon19medi-cal and 11 physical impairment categories (19) . The scores are compiled into asummaryscorerepresenting mild (0 or 1), moderate(2), or severe comorbidity (3).
Assayfor HIA
We utilisedastandard enzyme-linked immunosorbent assay (ELISA) forHIA, the GTI-PF4 enhanced assay(GeneticT esting Institute,W aukesha,W I), whichd etectsI gG, IgM andI gA directed against plateletfactor 4(PF4) boundtopolyvinylsulfonate (6, 20) .All assays were performedinduplicate(45 samples, apositive control, anegativecontrol andablankper each 96-wellplate) by blinded investigators anda ccording to the manufacturer'si nstructions.Absorbancefor positivecontrols hadtobe≥1.8 units, negative controls ≤0.3 units;ifthe mean of the sample absorbance ≥0.4 units, the test wasconsideredpositive.To detect false-positive results, such as when antibodiesare directed against heparin alone or when antibodiesa re non-specific, the heparinn eutralisation procedure (HNP) wasperformedaccording to the manufacturer's instructions.Aninhibition of apositiveresult by morethan50% in the presenceofheparin is consideredconfirmatoryfor HIA.
Qualitycontrol,correction procedure,and heparin neutralisation ELISA results were validatedonaper-plate and per-assaybasis. Plateswere consideredvalid if no morethan four sample results exceeded the limits for the coefficient of variability (CV>15%) and if the positive/negative control criteriawere met. Forindividual assays, the manufacturert olerates2 0% variability of the mean of the twosamples;w eapplied amore stringent CV criterion of 15%. Anyindividual sample with acoefficient of variability exceeding 15%was consideredinvalid if the mean absorbance was ≥0.150. Tests with amean absorbance value <0.15 were considered to be valid,regardless of the CV,astheywere clearly negative.F orty-nine blindedquality control samples were analysed. Due to the quality control criteria, 0.6% of samples (5/789) butno(0/18) whole plates had to be retested. Agreement for 49 pairsofblindedquality control samples was90% with a kappa value of 0.4.
In agreementw ith the manufacturer'ss pecifications intraplate variability of results wasm inimal( mean coefficient of variability (CV) for positive controls was1 .86 ±1 .32%, range 0.06-4.83%).W eo bserveda ni nterplate variability rangef or positivec ontrols of 2.3-3.6. According to the manufacturer's specifications anyresult ≥1.8isacceptable for positive controls, resulting in atheoreticalrangeof1. 8-3.6 . This illustratesthat the same sample measuredondifferent plates can give results that vary by 64% (asobserved) or 100% (in theory). Our resultssuggest that, due to the assaycharacteristics, resultsfrom different plates can only be evaluatedo nac ategorical scale (positive/ negative). To permit evaluation of optical density (OD) results on ac ontinuous scale we designedac orrection proceduret hat allowedu st oc ompareO Dv alues stemming from different plates. Forthis proceduremean OD valueswere calculated forall platesafter exclusion of extremeODvalues (<0.1and >1.0). The meanODv alues were normalisedtothe meanODofanindex plate defined to have acorrection coefficient of 1. All results on an individual plate( includingt he extremev alues)w ere then multipliedb yt he plate'sc orrection coefficient. When this perplate correction procedurew as performed,t he quality control parametersi mproved to 93% agreement and ak appav alue of 0.6, respectively.
Data analysis
We compared patient characteristics by HIA status usingP earson'sChi 2 tests for categorical variablesand analysis of variance for continuous variables. We used logistic regression to examine the association between HIA status and incidenceofthrombocytopenia. Coxp roportionalh azardsm odels were used to assess the strength and independenceo fa na ssociation between HIA status and arterial cardiovascular events, deep vein thrombosis/ pulmonary embolism, vascularaccessocclusion, and mortality. Relative hazards for these eventswere calculated by HIA status usingtime from first dialysis to deathorcensoring (at transplant, loss to follow-up, or closeout) as the survivaltime variable.Variableswere chosenfor adjustment (e.g. race,ICED,age at enrolment, and baseline albumin level) in the regression models based on eithertheir demonstration to be confoundersorprior evidence of their association with the outcome in question. All analyses were performed using Stata version 8.1( StataCorp,C ollege Station, TX, USA).
Patients at the same clinic cannot be consideredindependent observations (21) . We accounted fort his by obtaining robust variance-covariance matrix estimatesi na ll logistic regression and Coxproportionalhazardsmodels (stata option cluster) (22 
Results
HIA prevalence
Antibodies directed againstheparin/PF4 were detected in nearly 20%ofpatients earlyafter treatment initiation ( Fig. 2) and at six months following initiation of dialysis seventy-six of 740 (10.3%)patients hadapositiveHIA assay (Table 1) .Insamples takenatlater time points after HD initiation, the prevalencewas lower. Forpatients receiving PD,the prevalencewas stable over time at 9%.Patient characteristics by antibodypositivity at study inclusion are depictedinTable 2. There were no significant differences between the HIA-positive and -negativeg roups by demographics, comorbidity score, cardiovascularrisk factors, or relevant laboratorydatawith the exception of asmokinghistory at study inclusion.
HIA and thrombocytopenia
Mean platelet countswere lowerinHIA-positive patients butdid not differ significantly from thoseinHIA-negative patients at the timeofantibody testing ( Table 2 ). The presenceofHIA didnot predict subsequent thrombocytopenia at three( p=0.89), six (p=0.56), or nine months (p=0.76) after measurement.
HIA and clinical outcome
Survivalanalyses showednoassociation between positive HIA status and anyofthe clinicaloutcomes ( Table 3) . Atotal of 372 arterial eventsw ere recorded in 678 individuals. The corresponding numbers were 7and 737 for venous thromboembolism,86and 601 for venous access occlusion, and 448 and 732 for mortality.The discrepancybetween the number of patients in the study(740) and the number of individuals cited above is due to eventstaking place prior to HIAtesting and missing covariates. Theh ighest hazard ratio (HR)w as 1.4f or the association betweenHIA and venous thromboembolism butthe confidenceinterval(CI)was wide and included1.0. Unadjusted and adjusted resultsyieldedsimilarresults. Survivalanalysis performed on corrected(seeper-plate correction procedure under methods; shown)and uncorrecteddata (not shown) yieldedthe same results. The resultsofthe survival analyses were alsot he same when we analysed allp ositive samples (n=76) or onlythe ones confirmed by HNP (n=66).
HIT and HIT-relatedthrombosis
Ninepatients hadresults compatible with HIT, defined as apositive HIA assaya nd thrombocytopenia in the ensuing three months (9/740, 1.2%).The meanminimalplateletcount of the potential HITp atients during their thrombocytopenic episode was124 (range 106-147). One of the nine patients had thrombocytopenia as defined by ar elatived rop of platelet count by morethan 50%. All nine patients with potential HITwere receiving HD.O ne patient with potential HITh ad av enous thromboembolic event (1/740,0.13%) resulting in aHRof13.7 (95% CI 1.63-115.5) for HITand thrombosis.Six out of nine potential HITpatients' (including the patient with thrombosis) ELISAresults were confirmed by the HNP.
Discussion
We have demonstrated that approximately 10% of CKD patients treatedb yd ialysis develop HIAa ts ix months. Most previous studiess uggestedal ower prevalenceo fH IA in HD patients ranging from 0t o8 .8% (23) (24) (25) (26) (27) (28) (29) (30) (31) with one exception at 17.9% (32) .I nt hese studies, screening waso ften limitedt op atients with thrombocytopenia or thrombotic complications.F urthermore,the assayusedtodetect HIA and timing of the test variedacross studies. While most of these studieshavenot shown a correlation of HIAwith adverseoutcomes (29, 32) , othershave (30, 31) . Limitations of these studies included small patient cohorts (n<100) (23, 24, 27, (29) (30) (31) , fewert han 10 HIAp ositive patients (23-27, 30, 31) , or study design that not did allowprospectiverecording and assessmentofmultiple clinicaloutcomes. None of these studies reported quality control and/or performanceofHNP.
In theabsenceofthrombocytopenia, we found thatHIA positivity wasnot associated with adverse outcomes including arterial cardiovascularevents, venous thromboembolic events, vascular accessocclusion, and mortality.Our data,aswellasdatafrom prospective studiesi np opulations without CKD (5, 7, 20, 33) and with CKD (24, 29) , supportthe hypothesis that adverse cardiovascularevents associated with HIArequirethe activation of platelets by HIA, whichm anifests as thrombocytopenia.O ur findings aren ot consistent with the model in whichH IA-mediated platelet activation is bypassedand in whichthereisdirect HIA-mediated activation of target cells suchasendothelial cells or monocytes (1, 2, 34) .
There is arecently published study by Carrieretal. whichreportsthat IgG specific HIAfound in nine of 419 patients (univariate HR 2.40,9 5% CI 0.98 -5.89; multivariate HR 2.68, 95%CI1.08-6.63) areassociatedwith increased mortality in HD patients. Theauthors also looked at non IgG specific HIA-using the same test thatw eused-intheir patient population. No association betweenn on-specific HIAa nd mortality wasf ound (35) .Our study confirms the resultsofCarrier et al.inthat 12.9% were HIA positive (using the non IgG-specificassay) while we found 10.3%s eropositive patients. The study by Carriere ta l., however, does not reporto np lateletc ount. One cant hus not evaluate and differentiate the outcome of HIA-positive thrombocytopenicpatients, i.e.those with true HITfrom thatofHIA positive non-thrombocytopenic patients. We looked at HIA status and platelet count and foundn oi ncreased mortality of Ta ble3:Adjustedrisk of adverse events by thepresence of HIA at baseline.
other adverseo utcome in the HIAp ositiven on-thrombocytopenic group. There is literatureshowing that IgG-specific HIA testing offers enhancedtestcharacteristics as comparedtonon IgG-specific HIAtests (36) . However, there are alsodatashowing that non IgG-mediated forms of HITo ccur (37) .T his togetherwith the aspect thatatthe timeofstudy design there were only twomarketed,clinically validatedand Food and Drug Administration (FDA) approved tests available(both were nonIgGspecific, one of whichw ec hose for this study) motivatedo ur choiceofHIA assay. In this studyweexamined 740 patients, including nearly600 HD patients. HIAtesting wasperformed by blindedinvestigators using astandardised protocol with rigorousquality control, and HNP wasp erformed to rule out false-positive results. Clinical outcomesw ere collected fromm ultiple sources, and all events were validated. Limitations of our studyi nclude ap otential underestimation of the frequencyo fH IT-related events. As we testedHIA statusatsix monthsafter HD initiation, anycardiovascularevents in patients whose seroconversion occurred after the initialtesting would be missed. However, late seroconversion is less likelyt han seroconversion close to the time of heparin initiation. Finally, we did not assess the persistenceofHIA until the time of the event.
Previously,o ne study describedt emporal aspectso fH IA prevalenceinpatients acutelyexposed to heparin (20) .Onlylimiteddataare availablefor chronicallyexposed patients. Mean timebetween starting of HD and development of HITinaUK survey was61days(range5-390) (38) .W edid not seriallyfollowupour dialysis patients, our study nonetheless givesinsight into the temporalaspectsofHIA seroconversion in this type of heparine xposure (Fig. 2) . The above mentioned findings are compatible with amodel in whichasubset of heparin-exposed patients have apropensity to develop HIAand in whicha"time window" exists during whichH IA formation is most likelyt o occur.According to this hypothesis the large majority of patients will develop HITw hen both conditions arem et.T he "time window" mayv aryd epending on duration and type of heparin exposure as well as the clinical setting. As the UK survey and our datas uggest chronic intermittent exposure in dialysis patients maylead to atime windowofseveral weeks to months, whereas foracuteheparin exposure the timeofmaximum risk appears to be from day4today 14 (4) .
The high prevalenceo fH IA in PD patients remains unexplained. All HIAinPDpatients were showntobeheparin-specificthrough the HNP,w hich detects false-positive results (see Table2 ) . PD patientsa re notr outinelye xposed to therapeutic doses of heparin. Theymay,however,beexposed to heparin in intravenous flushes, heparin additivestodialysis fluids, heparin prophylaxis at time of immobilisation and other situations with increased venous thromboembolic risk or also during angiographic procedures.
We concludethat although thereisahigh prevalenceofHIA of the IgG, IgA or IgM class, these antibodiesdirected against heparin/PF4 (as detected in anon IgG-specific assay) in the absenceofthrombocytopenia arenot associated with cardiovascular eventsorincreased mortality in patients on dialysis. Our resultsdonot supportthe hypothesis that HIAlead to adverseclinical outcomesinthe absence of plateletactivation. In addition to giving insight into the pathophysiology of HIT, our data have implications for monitoring and therapeutic guidelines. Firstly,our data suggest that following the initiation of dialysis monitoring of HIAantibodies is not warranted in patients in the absence of thrombocytopenia or clinical evidences uggestive of HIT. Secondly, our data provide no evidencethat would justify switching from heparin to an alternativepotentiallymore expensive anticoagulant in dialysis patients whoare HIA positive and non-thrombocytopenic. Finally, the data provide reassurance thatthe induction of HIAbychronic intermittent exposure to heparin is not associated with ah igh risk of adverse outcomesi np atients with CKD treated by dialysis.
